+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drug Delivery Across Blood Brain Barrier Market by Technology, Drug Type, Therapeutic Application, Route of Administration, End User - Global Forecast to 2030- Product Image
Drug Delivery Across Blood Brain Barrier Market by Technology, Drug Type, Therapeutic Application, Route of Administration, End User - Global Forecast to 2030- Product Image
Sale

Drug Delivery Across Blood Brain Barrier Market by Technology, Drug Type, Therapeutic Application, Route of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5337118
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drug Delivery Across Blood Brain Barrier Market grew from USD 726.97 million in 2024 to USD 796.26 million in 2025. It is expected to continue growing at a CAGR of 9.09%, reaching USD 1.22 billion by 2030.

Navigating Complex Pathways to the Brain Barrier

The delivery of therapeutics across the blood-brain barrier remains one of the most formidable challenges in modern medicine. Tight junctions, efflux transporters, and a selectively permeable endothelium ensure optimal neural homeostasis but also impede the effective transport of life-saving compounds. As neurodegenerative disorders, brain tumors, and central nervous system infections continue to rise, the demand for innovative delivery platforms that can safely and efficiently traverse this barrier has reached unprecedented levels.

This executive summary distills critical insights on the evolving competitive landscape, regulatory shifts, and technological breakthroughs enabling targeted brain delivery. It outlines key segmentation dynamics, regional strengths, and the cumulative impact of United States tariffs introduced in 2025. Industry stakeholders will find a clear framework for understanding market drivers, potential bottlenecks, and strategic opportunities that define the next frontier in blood-brain barrier therapeutics.

Revolutionizing Brain-Targeted Therapies Through Innovative Breakthroughs

In recent years, a wave of scientific advances has upended traditional approaches to central nervous system drug delivery. Exosomes have emerged as natural nanocarriers with inherent biocompatibility that can be engineered to ferry small molecules and biologics directly to neural tissue. Concurrently, peptide-based carriers are being optimized to exploit receptor-mediated transcytosis mechanisms, offering enhanced specificity.

Meanwhile, regulatory agencies are adopting adaptive approval pathways that encourage collaboration between industry and academia. This new regulatory environment has spurred partnerships between biotech innovators focusing on viral vectors and established pharmaceutical companies specializing in large-molecule formulation. Digital modeling and in silico screening tools now accelerate candidate selection, enabling faster translation of preclinical findings into early-phase clinical trials. As a result, the landscape of brain-targeted therapies is undergoing a fundamental shift from incremental improvements toward transformative multimodal platforms.

Assessing the Ripple Effects of US Tariffs on Supply Chains and Costs

The United States introduced a series of tariffs in 2025 that have reverberated throughout global supply chains for advanced drug delivery components. Key raw materials for lipid-based nanocarriers, including specialized lipids and surfactants, have seen cost escalations that challenge manufacturers’ margin structures. Contract research organizations and clinical-scale producers have responded by diversifying suppliers across Asia-Pacific hubs and forging strategic alliances with domestic suppliers to mitigate exposure.

Moreover, viral vector production has been impacted by tariffs on plasmid DNA enzymes and specialized bioreactor consumables. Companies have accelerated investments in process intensification and continuous manufacturing to offset higher input prices. While these adjustments have introduced short-term operational complexities, they have also catalyzed greater resilience and encouraged supply chain localization strategies that may ultimately reduce lead times and ensure consistent product quality.

Unpacking Market Dynamics Across Diverse Delivery Platforms and Therapies

Market segmentation reveals nuanced performance across various delivery technologies. Exosomes are gaining traction for their natural targeting capabilities, while nanocarriers-spanning dendrimers, liposomes, polymeric nanoparticles, and solid lipid nanoparticles-are being refined to enhance payload capacity and circulation stability. Peptide-based carriers leverage custom sequences to navigate receptor-mediated uptake, and viral vectors continue to evolve with improved safety and transduction efficiency.

Distinctions between biologics and small molecules shape product pipelines. Biologics, encompassing gene therapies, monoclonal antibodies, and peptides & proteins, demand sophisticated carrier platforms to maintain molecular integrity en route to the brain. Small molecules benefit from simpler formulation strategies but often require higher dosing or permeability enhancers.

Therapeutic applications further stratify the market, from aggressive brain tumor protocols to targeted treatments for infectious and neurodegenerative diseases, as well as psychiatric disorders. Administration routes-convection-enhanced delivery, intra-arterial infusion, intranasal sprays, and intravenous injections-are selected based on disease state, patient compliance, and invasiveness thresholds. Finally, end users such as contract research organizations, home care settings, hospitals & clinics, and research institutes drive demand through varied adoption patterns and funding models.

Comparative Regional Dynamics Shaping Adoption Across Global Markets

Global adoption patterns highlight distinct regional strengths. In the Americas, well-established clinical infrastructures and robust funding mechanisms accelerate clinical trial initiation for novel carriers and biologic formulations. Partnerships between academic centers and pharmaceutical sponsors drive high-volume testing for cutting-edge gene therapies and viral vectors.

Europe, Middle East & Africa exhibit a regulatory mosaic, with some markets offering accelerated access schemes for breakthrough therapies while others adhere to more conservative pathways. This divergence encourages companies to tailor their regulatory strategies regionally, optimizing dossier preparation and leveraging conditional approvals where available.

Asia-Pacific markets have emerged as competitive manufacturing hubs for both small molecule and biologic carriers. Lower production costs and supportive government incentives in select countries have attracted significant capacity expansions. Rapid digital health adoption further fuels remote monitoring and patient enrollment in intranasal and non-invasive delivery trials.

Strategic Positioning of Key Stakeholders in the Emerging Marketplace

Leading pharmaceutical and biotechnology companies are redefining market standards through strategic alliances and targeted R&D investments. Global giants are integrating proprietary nanocarrier platforms into established pipelines, while biotechs are partnering with leading research institutes to accelerate clinical proof of concept for exosome-based therapies.

In parallel, specialized contract development and manufacturing organizations are scaling cGMP production of complex biologics and viral vectors, supporting both early-stage trials and commercial launches. Academic spinouts are disrupting the landscape by translating platform innovations into spin-off ventures focused on precision delivery. Together, these stakeholders form an interconnected ecosystem that balances agility with the resources needed to bring advanced therapies to patients.

Actionable Strategies to Accelerate Brain-Barrier Drug Delivery Innovation

Industry leaders should prioritize the optimization of carrier platforms that demonstrate both safety and scalability. Investing in modular manufacturing technologies will enable rapid pivoting between formulations and support combination therapies. Engaging proactively with regulatory authorities to pursue accelerated approval pathways can shorten timelines and de-risk clinical investments.

Collaborating across the value chain-linking platform developers, clinical research sites, and commercial partners-will create unified roadmaps for late-stage development and market access. Incorporating digital health solutions into trial protocols can enhance patient monitoring and generate real-world evidence to support reimbursement discussions. Finally, establishing flexible supply chain strategies that leverage regional strengths will safeguard against future trade disruptions and cost variability.

Robust Research Framework Boosting Confidence in Market Conclusions

This analysis draws on a multi-tiered research framework combining extensive secondary research with primary interviews conducted across pharmaceutical executives, clinical researchers, regulatory experts, and technology providers. Data sources include peer-reviewed publications, regulatory filings, corporate disclosures, and proprietary patent databases. Findings were triangulated through cross-referencing quantitative evidence with qualitative insights obtained from key opinion leaders.

Rigorous validation processes ensured data integrity, including double-blind reviews of critical inputs and scenario assessments to test sensitivity across various market drivers. Segmentation was applied methodically across technology, drug type, therapeutic application, route of administration, and end user to deliver a comprehensive and coherent narrative. This robust approach underpins the reliability of conclusions drawn and reinforces the strategic recommendations presented.

Charting the Next Frontier in Blood-Brain Barrier Therapeutics

The landscape of drug delivery across the blood-brain barrier is at a pivotal juncture. Technological breakthroughs, shifting regulatory paradigms, and evolving competitive strategies converge to create unprecedented opportunities. Navigating this complexity demands a clear understanding of market segmentation, regional dynamics, and external pressures such as tariffs.

By synthesizing these insights, stakeholders can chart a path toward next-generation therapies that transform patient outcomes. Embracing innovation while maintaining operational resilience will be crucial as the industry moves from research to commercialization in this high-stakes arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Technology
    • Exosomes
    • Nanocarriers
      • Dendrimers
      • Liposomes
      • Polymeric Nanoparticles
      • Solid Lipid Nanoparticles
    • Peptide-Based Carriers
    • Viral Vectors
  • Drug Type
    • Biologics
      • Gene Therapy
      • Monoclonal Antibodies
      • Peptides & Proteins
    • Small Molecules
  • Therapeutic Application
    • Brain Tumors
    • Infectious Diseases
    • Neurodegenerative Diseases
    • Psychiatric Disorders
  • Route Of Administration
    • Convection-Enhanced Delivery
    • Intra-Arterial
    • Intranasal
    • Intravenous
  • End User
    • Contract Research Organizations
    • Home Care Settings
    • Hospitals & Clinics
    • Research Institutes
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Johnson & Johnson
  • Roche Holding AG
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • AstraZeneca PLC
  • GSK plc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drug Delivery Across Blood Brain Barrier Market, by Drug Type
8.1. Introduction
8.2. Biologics & Large Molecules
8.2.1. Peptides
8.2.2. Proteins
8.3. Nanoparticles
8.3.1. Lipid Nanoparticles
8.3.2. Polymeric Nanoparticles
8.4. Small Molecules
8.5. Viral Vectors
8.5.1. Adenoviral Vectors
8.5.2. Lentiviral Vectors
9. Drug Delivery Across Blood Brain Barrier Market, by Delivery Method
9.1. Introduction
9.2. Intranasal
9.2.1. Inhalation
9.2.2. Spray
9.3. Intrathecal
9.4. Intravenous
9.5. Orthotopic Direct Injection
9.5.1. Cranial Injection
9.5.2. Stereotactic Surgery
10. Drug Delivery Across Blood Brain Barrier Market, by Therapeutic Application
10.1. Introduction
10.2. Genetic Disorders
10.2.1. Metachromatic Leukodystrophy
10.2.2. Phenylketonuria
10.3. Neurodegenerative Disorders
10.3.1. Alzheimer's Disease
10.3.2. Parkinson's Disease
10.4. Oncology
10.4.1. Glioblastoma
10.4.2. Medulloblastoma
11. Drug Delivery Across Blood Brain Barrier Market, by Carrier Systems
11.1. Introduction
11.2. Liposomal Carriers
11.3. Monoclonal Antibodies
11.3.1. Antibody-Drug Conjugates
11.4. Polymeric Carriers
11.4.1. Dendrimers
11.4.2. Polymersomes
12. Drug Delivery Across Blood Brain Barrier Market, by Development Stage
12.1. Introduction
12.2. Clinical Trials
12.2.1. Phase I
12.2.2. Phase II
12.2.3. Phase III
12.3. Post-Marketing
12.4. Pre-Clinical
12.5. Research & Development
13. Americas Drug Delivery Across Blood Brain Barrier Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Drug Delivery Across Blood Brain Barrier Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Drug Delivery Across Blood Brain Barrier Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. 3M Company
16.3.2. AbbVie Inc.
16.3.3. Angiochem Inc.
16.3.4. Bioasis Technologies Inc.
16.3.5. Boehringer Ingelheim International GmbH
16.3.6. Bristol-Myers Squibb Company
16.3.7. Carthera S.A.
16.3.8. CNS Pharmaceuticals, Inc.
16.3.9. Cordance Medical Inc.
16.3.10. F. Hoffmann-La Roche Ltd.
16.3.11. ICON PLC
16.3.12. JCR Pharmaceuticals Co., Ltd.
16.3.13. Nanoform Finland Oyj
16.3.14. Ossianix, Inc.
16.3.15. Pfizer Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET MULTI-CURRENCY
FIGURE 2. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET MULTI-LANGUAGE
FIGURE 3. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ADENOVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY LENTIVIRAL VECTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY SPRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CRANIAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STEREOTACTIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PHENYLKETONURIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MEDULLOBLASTOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY LIPOSOMAL CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POST-MARKETING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 111. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 112. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 113. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 114. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 115. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 116. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 117. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 118. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 120. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 121. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 122. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 123. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 124. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 125. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 126. CANADA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 129. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 130. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 131. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 132. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 133. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 137. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 138. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 140. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 142. MEXICO DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 193. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 195. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 196. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 197. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 198. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 199. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 200. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 202. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 203. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 204. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 205. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 206. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 207. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 208. CHINA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 209. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 210. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 211. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 212. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 213. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 214. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 215. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 216. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 218. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 219. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 220. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 221. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 223. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 224. INDIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 239. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 240. INDONESIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 241. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 243. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 244. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 245. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 246. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 247. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 248. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 249. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 250. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 251. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 252. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 253. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 254. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 256. JAPAN DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY BIOLOGICS & LARGE MOLECULES, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY VIRAL VECTORS, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ORTHOTOPIC DIRECT INJECTION, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CARRIER SYSTEMS, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY POLYMERIC CARRIERS, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES DRUG DELIVERY ACROSS BLOOD BRAIN BARRIER MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 274. PHILIPPINES DR

Companies Mentioned

The companies profiled in this Drug Delivery Across Blood Brain Barrier market report include:
  • Johnson & Johnson
  • Roche Holding AG
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • AstraZeneca PLC
  • GSK plc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 796.26 Million
Forecasted Market Value ( USD ) by 2030 $ 1220 Million
Compound Annual Growth Rate9.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions - Product Image

Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration, Target Disease Indication, Therapeutic Area and Key Geographical Regions

  • Report
  • 375 Pages
  • Global
From
Drug Delivery Across Blood Brain Barrier Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Drug Delivery Across Blood Brain Barrier Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Drug Delivery Across Blood Brain Barriers - Global Strategic Business Report - Product Image

Drug Delivery Across Blood Brain Barriers - Global Strategic Business Report

  • Report
  • 297 Pages
  • Global
From
Blood Brain Barrier Technologies Market Report 2025 - Product Image

Blood Brain Barrier Technologies Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors - Product Image

Nanotechnology-Based Targeted Drug Delivery Systems for Brain Tumors

  • Book

About the Blood Brain Barrier Drug Delivery Market

The Blood Brain Barrier Drug Delivery market is a subset of the larger Drug Delivery market. It focuses on the development of drugs that can cross the blood-brain barrier, a protective layer of cells that separates the brain from the rest of the body. These drugs are used to treat neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. The Blood Brain Barrier Drug Delivery market is highly competitive, with companies investing heavily in research and development to create new drugs and delivery systems. The market is driven by the increasing prevalence of neurological diseases, as well as the need for more effective treatments. Additionally, advances in technology have enabled the development of more efficient drug delivery systems. Some companies in the Blood Brain Barrier Drug Delivery market include AbbVie, AstraZeneca, Biogen, Eli Lilly, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.